Clopidogrel Bisulfate
Product Images NDC 67046-099

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 67046-099). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Contract Pharmacy Services-pa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container1 (Conatiner1)

Label for Clopidogrel bisulfate tablets, 75 mg strength, 30 count. The label includes instruction to see package insert for dosage, storage temperature recommendations (20-25°C), and the active ingredient equivalency. Packaged by Contract Pharmacy Services-PA, with an NDC of 67046-099-30.*

FDA Label Image

Figure1 (Figure1)

A horizontal error bar chart illustrating the effect of co-administered proton pump inhibitors (PPIs) Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg on the active metabolite area under the curve (AUC) with mean values and 90% confidence intervals shown.*

FDA Label Image

Figure2 (Figure2)

A line graph showing cumulative event rates (%) over 12 months of follow-up, comparing Clopidogrel plus aspirin treatment to placebo plus aspirin. The graph indicates a lower event rate for Clopidogrel plus aspirin throughout the follow-up period, with a p-value of 0.00009 noted. A footnote mentions the use of other standard therapies as appropriate.*

FDA Label Image

Figure3 (Figure3)

A forest plot chart showing hazard ratios with 95% confidence intervals comparing Clopidogrel bisulfate and placebo across various patient subgroups including age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, previous stroke, use of heparin/LMWH, aspirin dosage, use of GPIIb/IIIa antagonists, beta-blockers, and ACE inhibitors. The chart visually indicates whether the results favor Clopidogrel or placebo for each subgroup and overall outcomes.*

FDA Label Image

Figure4 (Figure4)

A Kaplan-Meier survival curve showing the percentage of deaths before first discharge over 28 days since randomization, comparing Clopidogrel bisulfate and placebo groups. The graph includes cumulative death percentages, total deaths for each group, and notes a 7% proportional risk reduction with Clopidogrel bisulfate (p=0.03).*

FDA Label Image

Figure5 (Figure5)

A Kaplan-Meier curve chart showing the percentage of patients with death, reinfarction, or stroke before first discharge over 28 days since randomization. The graph compares outcomes between placebo and Clopidogrel groups, indicating lower event rates with Clopidogrel and a noted 9% proportional risk reduction.*

FDA Label Image

Figure6 (Figure6)

A forest plot chart depicting odds ratios with 99% confidence intervals comparing the effect of Clopidogrel bisulfate versus placebo across various subgroups. Subgroups include gender, age at entry, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use. The horizontal axis shows odds ratios from 0.6 to 1.3 with a central line at 1.0 for reference.*

FDA Label Image

Figure7 (Figure7)

A line graph showing cumulative event rates over 36 months of follow-up, comparing fatal or non-fatal vascular events between aspirin and clopidogrel. The vertical axis represents cumulative event rate percentage from 0 to 16%, and the horizontal axis shows months of follow-up from 0 to 36. The graph includes a noted p-value of 0.045.*

FDA Label Image

Figure8 (Figure8)

A hazard ratio forest plot comparing Clopidogrel bisulfate and Aspirin for various qualifying conditions including Stroke, MI, PAD, and Overall. The chart displays the number of subjects in each treatment group and visually indicates favoring either Clopidogrel or Aspirin with confidence intervals along a numerical hazard ratio scale ranging roughly from 0.6 to 1.3.*

FDA Label Image

Structure (Structure)

Chemical structure of clopidogrel bisulfate showing the molecular arrangement including a thiophene ring, a bicyclic structure, and associated functional groups, as well as the bisulfate component (H2SO4).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.